Citations

Showing 10 of 108119 citations.

Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies.
Lewis, Karl D. , Sekulić, Aleksandar , Migden, Michael R. , Oro, Anthony E. , LoRusso, Patricia , Hainsworth, John D. , Williams, Sarah, Hou, Jeannie , Hoff, Daniel D. Von , Hauschild, Axel , Rudin, Charles M. , Dirix, Luc , Solomon, James A.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 9012-9012

10.1200/jco.2014.32.15_suppl.9012 Get It

The Mayo Clinic experience with the use of kinase inhibitors (KIs), ipilimumab, and bevacizumab in the treatment of metastatic ocular melanoma.
Moser, Justin C. , Pulido, José S. , Dronca, Roxana , Markovic, Svetomir, Markovic, Svetomir N. , Mansfield, Aaron S.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e20011-e20011

10.1200/jco.2014.32.15_suppl.e20011 Get It

ECOG multiple myeloma (MM) clinical trial (CT) accrual performance evaluation utilizing the NCI–Trial Complexity and Elements Scoring (NCI-TCES) and the NCI Myeloma Steering Committee Accrual Working Group (NCI MYSC AWG) scoring models.
Weiss, Matthias , Jacobus, Susanna , Munshi, Nikhil C. , Kumar, Shaji , Lacy, Martha Q. , Stewart, A. Keith, Friedenberg, William R., Kyle, Robert A. , Greipp, Philip R., Gertz, Morie A. , Lonial, Sagar , Fonseca, Rafaël , Dispenzieri, Angela , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8600-8600

10.1200/jco.2014.32.15_suppl.8600 Get It

Free light chain assay and cytogenetic abnormalities for identification of high-risk smoldering myeloma.
Larsen, Jeremy T. , Kumar, Shaji , Esplin, Brandt L., Morice, William G. , Kyle, Robert A. , Gonsalves, Wilson I. , Gupta, Vinay Kumar , Ketterling, Rhett P. , Morice, William George , Dispenzieri, Angela , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8595-8595

10.1200/jco.2014.32.15_suppl.8595 Get It

Older patients and risk of developing and dying from bleomycin-induced lung toxicity.
Marri, Preethi, Ristow, Kay M., Rodriguez, Vilmarie , Ansell, Stephen M. , Habermann, Thomas M.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8584-8584

10.1200/jco.2014.32.15_suppl.8584 Get It

Stage migration and survival in DLBCL patients before and after the approval of positron emission tomography (PET) scan: Population-based analysis using the U.S. National Cancer Data Base (NCDB).
Madadi, Anusha R., Al‐Hamadani, Mohammed , Go, Ronald S.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8561-8561

10.1200/jco.2014.32.15_suppl.8561 Get It

Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma.
Ali, Siraj M. , He, Jie , Chmielecki, Juliann , Pinder, Mary , Akerley, Wallace , Wang, Kai , Molina, Julian R. , Yelensky, Roman , Palmer, Gary A. , Morosini, Deborah, Lipson, Doron , Stephens, Phil , Salgia, Ravi , Miller, Vincent A. , Ou, Sai‐Hong Ignatius , Peled, Nir , Pinder, Mary Colleen, Palma, Norma Alonzo , Ross, Jeffrey S , Frampton, Garrett M. , Bazhenova, Lyudmila

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8049-8049

10.1200/jco.2014.32.15_suppl.8049 Get It

Phase 1-2 open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of intravenous infusion of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A) in patients (pts) with relapsed or refr
Bensinger, William, Novitzky, Nicolás , McDonald, Andrew , Gutierrez, Martin , Libby, Edward N., Thompson, John E., Bexon, Alice, Barranco, Charles, Taylor, Catherine , Dondero, Richard, Browne, Leslie J., Kurman, Michael R., Lust, John A., Craig, Michael , Siegel, David S. , Rhee, Frits van

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS8616-TPS8616

10.1200/jco.2014.32.15_suppl.tps8616 Get It

Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study.
Ansell, Stephen M. , Younes, Anas , Gallamini, Andrea , Kim, Won Seog , Friedberg, Jonathan W. , Feldman, Tatyana , Bartlett, Nancy L. , Wang, Jingyuan , Brady, Kelly, Sachs, Jessica, Huebner, Dirk, Hunder, Naomi, Radford, John , Bartlett, Nancy L , Connors, Joseph M. , Collins, Graham P. , Radford, John

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS8613-TPS8613

10.1200/jco.2014.32.15_suppl.tps8613 Get It

Identification of independent primary tumors and intra-pulmonary metastasis using DNA rearrangements in non-small cell lung cancer.
Aubry, Marie‐Christine, Harris, Faye R. , Johnson, Sarah H. , Terra, Simone Barreto Siqueira Parrilha, Peikert, T., Yi, Eunhee S. , Vasmatzis, George , Wigle, Dennis A. , Murphy, Stephen J. , Aubry, Marie-Christine, Asiedu, Michael K. , Yang, Ping

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e18515-e18515

10.1200/jco.2014.32.15_suppl.e18515 Get It